Related Experiment Video
Updated: Jun 17, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Unnatural polyketide analogues selectively target the HER signaling pathway in human breast cancer cells
Seok Joon Kwon1, Moon Il Kim, Bosung Ku
1Department of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
Abstract:
Receptor tyrosine kinases are critical targets for the regulation of cell survival. Cancer patients with abnormal receptor tyrosine kinases (RTK) tend to have more aggressive disease with poor clinical outcomes. As a result, human epidermal growth factor receptor kinases, such as EGFR (HER1), HER2, and HER3, represent important therapeutic targets. Several plant polyphenols including the type III polyketide synthase products (genistein, curcumin, resveratrol, and epigallocatechin-3-galate) possess chemopreventive activity, primarily as a result of RTK inhibition. However, only a small fraction of the polyphenolic structural universe has been evaluated. Along these lines, we have developed an in vitro route to the synthesis and subsequent screening of unnatural polyketide analogues with N-acetylcysteamine (SNAc) starter substrates and malonyl-coenzyme A (CoA) and methylmalonyl-CoA as extender substrates. The resulting polyketide analogues possessed a similar structural polyketide backbone (aromatic-2-pyrone) with variable side chains. Screening chalcone synthase (CHS) reaction products against BT-474 cells resulted in identification of several trifluoromethylcinnamoyl-based polyketides that showed strong suppression of the HER2-associated PI3K/AKT signaling pathway, yet did not inhibit the growth of nontransformed MCF-10A breast cells (IC(50)>100 microM). Specifically, 4-trifluoromethylcinnamoyl pyrone (compound 2 e) was highly potent (IC(50)<200 nM) among the test compounds toward proliferation of several breast cancer cell lines. This breadth of activity likely stems from the ability of compound 2 e to inhibit the phosphorylation of HER1, HER2, and HER3. Therefore, these polyketide analogues might prove to be useful drug candidates for potential breast cancer therapy.
Insights
Novel polyketide analogues were synthesized and screened, with one compound showing potent inhibition of human epidermal growth factor receptor kinases (HER1, HER2, HER3) and suppression of breast cancer cell proliferation.
Area of Science:
- Biochemistry
- Molecular Biology
- Medicinal Chemistry
Background:
- Receptor tyrosine kinases (RTKs) are crucial for cell survival and are often dysregulated in aggressive cancers.
- Human epidermal growth factor receptor kinases (EGFR/HER1, HER2, HER3) are key therapeutic targets in breast cancer.
- Plant-derived polyphenols exhibit chemopreventive activity via RTK inhibition, but their structural diversity is vast and largely unexplored.
Purpose of the Study:
- To synthesize and screen novel unnatural polyketide analogues for their potential as breast cancer therapeutics.
- To investigate the inhibitory effects of these analogues on RTK signaling pathways.
- To identify specific compounds with potent and selective anticancer activity.
Main Methods:
- Developed an in vitro synthesis route for polyketide analogues using N-acetylcysteamine (SNAc) starter substrates and malonyl-coenzyme A (CoA) / methylmalonyl-CoA extenders.
- Screened chalcone synthase (CHS) reaction products against BT-474 breast cancer cells.
- Assessed inhibition of HER2-associated PI3K/AKT signaling pathway and proliferation of breast cancer cell lines.
Main Results:
- Identified several trifluoromethylcinnamoyl-based polyketide analogues with potent HER2-associated PI3K/AKT signaling suppression.
- Compound 4-trifluoromethylcinnamoyl pyrone (2e) demonstrated high potency (IC(50)<200 nM) against multiple breast cancer cell lines.
- Selective activity was observed, with no significant inhibition of nontransformed MCF-10A breast cells (IC(50)>100 microM).
- Compound 2e inhibited phosphorylation of HER1, HER2, and HER3, indicating broad RTK inhibition.
Conclusions:
- Synthesized polyketide analogues represent a promising class of compounds for breast cancer drug development.
- Compound 2e exhibits potent and selective inhibition of key oncogenic signaling pathways.
- These novel analogues may offer a new therapeutic strategy for breast cancer treatment by targeting multiple RTKs.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
02:34Inhibition of Cdk Activity